The Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) was requested by the European Commission (EC) to provide a scientific opinion on the safety of breast implants in relation to anaplastic large cell lymphoma (ALCL). There are several types of textured breast implants; surface textures of breast implants are not all manufactured in the same way, and breast implants with diverse surface textures may also present different benefits. The magnitude of the risk per type of textured implant is difficult to establish due to the low incidence of the breast implants associated anaplastic large cell lymphoma (BIA-ALCL). Therefore, risk assessments per implant type are needed. Overall SCHEER considers that there is a moderate weight of evidence for a causal relationship between textured breast implants and BIA-ALCL, particularly in relation to implants with an intermediate to high surface roughness.The pathogenic mechanisms are not fully elucidated; current hypotheses include genetic drivers, chronic inflammation resulting either from bacterial contamination, shell shedding of particulates, or shell surface characteristics leading to friction, or by implant associated reactive compounds. Reporting of new BIA-ALCL cases by the national clinical registries is critically important to obtain a better estimate of the risk of BIA-ALCL for patients with a breast implant.

Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: report of the scientific committee on health, emerging and environmental risks (SCHEER) / De Jong, W. H.; Panagiotakos, D.; Proykova, A.; Samaras, T.; Clemens, M. W.; De Jong, D.; Hopper, I.; Rakhorst, H. A.; Santanelli di Pompeo, F.; Turner, S. D.; Bertollini, R.; Borges, T.; de Jong, W.; de Voogt, P.; Duarte-Davidson, R.; Hoet, P.; Ion, R. M.; Kraetke, R.; Scott, M.; Testai, E.; Vermeire, T.; Vighi, M.; Zacharov, S.. - In: REGULATORY TOXICOLOGY AND PHARMACOLOGY. - ISSN 0273-2300. - 125:(2021), pp. 1-4. [10.1016/j.yrtph.2021.104982]

Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: report of the scientific committee on health, emerging and environmental risks (SCHEER)

Santanelli di Pompeo F.;Scott M.;Testai E.;
2021

Abstract

The Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) was requested by the European Commission (EC) to provide a scientific opinion on the safety of breast implants in relation to anaplastic large cell lymphoma (ALCL). There are several types of textured breast implants; surface textures of breast implants are not all manufactured in the same way, and breast implants with diverse surface textures may also present different benefits. The magnitude of the risk per type of textured implant is difficult to establish due to the low incidence of the breast implants associated anaplastic large cell lymphoma (BIA-ALCL). Therefore, risk assessments per implant type are needed. Overall SCHEER considers that there is a moderate weight of evidence for a causal relationship between textured breast implants and BIA-ALCL, particularly in relation to implants with an intermediate to high surface roughness.The pathogenic mechanisms are not fully elucidated; current hypotheses include genetic drivers, chronic inflammation resulting either from bacterial contamination, shell shedding of particulates, or shell surface characteristics leading to friction, or by implant associated reactive compounds. Reporting of new BIA-ALCL cases by the national clinical registries is critically important to obtain a better estimate of the risk of BIA-ALCL for patients with a breast implant.
2021
anaplastic large cell lymphoma; BIA-ALCL; breast implants; cancer
01 Pubblicazione su rivista::01a Articolo in rivista
Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: report of the scientific committee on health, emerging and environmental risks (SCHEER) / De Jong, W. H.; Panagiotakos, D.; Proykova, A.; Samaras, T.; Clemens, M. W.; De Jong, D.; Hopper, I.; Rakhorst, H. A.; Santanelli di Pompeo, F.; Turner, S. D.; Bertollini, R.; Borges, T.; de Jong, W.; de Voogt, P.; Duarte-Davidson, R.; Hoet, P.; Ion, R. M.; Kraetke, R.; Scott, M.; Testai, E.; Vermeire, T.; Vighi, M.; Zacharov, S.. - In: REGULATORY TOXICOLOGY AND PHARMACOLOGY. - ISSN 0273-2300. - 125:(2021), pp. 1-4. [10.1016/j.yrtph.2021.104982]
File allegati a questo prodotto
File Dimensione Formato  
De-Jong_Final-opinion_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 543.88 kB
Formato Adobe PDF
543.88 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1572075
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 40
social impact